{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-030866","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.827104+00:00","generated_at":"2026-06-21T12:55:43.889118+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arrowhead Pharma reports FY22 revenue up but net loss widens to $172.7M; $250M royalty sale","bullets":["Revenue $243.2M for FY22 (Sep 30 yr-end), up 76% from $138.3M in FY21.","Net loss $172.7M ($1.67 diluted loss per share) vs $140.8M ($1.36) prior year.","Sold olpasiran royalty interest to Royalty Pharma for $250M cash plus up to $160M milestones.","Phase 2 studies for ARO-APOC3 and ARO-ANG3 fully enrolled; new Phase 1/2a starts for ARO-MUC5AC, ARO-RAGE, ARO-MMP7.","Cash and investments $482.3M at Sep 30, 2022, down from $613.4M at Sep 30, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-030866","json":"https://secwatch.observer/filing/0001628280-22-030866.json","markdown":"https://secwatch.observer/filing/0001628280-22-030866.md","text":"https://secwatch.observer/filing/0001628280-22-030866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828022030866/0001628280-22-030866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828022030866/arwr-20221128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:55:43.889118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}